DDrare: Database of Drug Development for Rare Diseases

Searched query = "Bronchiolitis obliterans", "Obliterating bronchiolitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 5-Methyl-1-Phenyl-2-1-(H)-Pyridone; AZITHROMYCIN; AZITHROMYCIN DIHYDRATE; AZITHROMYCINE; AZITHROMYCINE 250 mg; AZM; Adipate; Aerolised Liposomal Ciclosporin A; Aerolised Liposomal Ciclosporin A 10mg; Aerolised Liposomal Ciclosporin A 5mg; Azithromycin; Azithromycin (Zitromax°); Azithromycin + N-acetylcystein + inhaled corticosteroid; Azithromycine; Aztreonam; Aztreonam Lysine for Inhalation (AZLI); Basiliximab; Bortezomib; Budesonide; Budesonide/formoterol; CICLOSPORIN A; COLECALCIFEROL; Certican; Certican 0,5; Certican 0,5 mg Tabletten; Certican 0,75mg; Certican 0,75mg Tabletten; Chloride; Ciclosporin; Ciclosporin (Ciclosporinium); Ciclosporina; Ciclosporina / Ciclosporin; Ciclosporina A Liposomica Aerolised Liposomal Ciclosporin A; Ciclosporina/ Ciclosporin; Ciclosporine; Ciclosporine A; Ciclosporine, Ciclosporina; Ciclosporine, ciclosporina; Clarithromycin; Cloruro de Sodio; Cloruro de sodio; Colecalciferol; CsA; Cyclosporine; Cyclosporine A dry powder inhalation (Drug); Cyclosporine Inhalation Solution; Cyclosporine Inhalation Solution (CIS); D-Cure; D-cure; ERL080; Enteric coated mycophenolate sodium; Erythromycin; Esbriet; Etanercept; Everolimus; FAM Therapy; Fluticasone; Fluticasone propionate; Formoterol; Formoterol/Budesonide; Glucocorticoid; Helium; Helium-3; Hp 129Xenon; Hyperpolarized Helium-3 MRI; INTERFERON GAMMA-1B; Imukin; Inhalation; Interferon Gamma; Interferon gamma 1b; Interferon gamma-1b; Itacitinib; Itacitinib Adipate; L-CsA; Lactose; Liposomal Cyclosporine A; Liposomal Cyclosporine A 10 mg; Liposomal Cyclosporine A 5 mg; Liposomal aerosol cyclosporine; Lysine; MONTELUKAST SODIUM; MPH966; MSCs; Mesenchymal stem cell 0.5; Mesenchymal stem cell 1.0; Montelukast; Montelukast Teva; Montelukast sodium; Montelukast teva; Mycophenolate; Myfortic; Nintedanib; OFEV; OTHER SOURCES; Other: EIT; Other: Inhaled Hyperpolarized Xenon-129; Other: Salbutamol nebulisation and with CPAP; Other: standard immune suppression, oral; PIRFENIDONE; Pirfenidone; Pirfenidone 267 MG [Esbriet]; Prednisone; Procedure: Pulmonary function testing; Procedure: Status Post Lung Transplant; RAD001; Ruxolitinib; Salbutamol; Seretide; Singulair; Singulair (Montelukast Sodium); Sodium Chloride; Sodium Chloride Solution; Sodium Chloride Solvent; Sodium Chloride solvent; Sodium chloride; Solucion de Cloruro de Sodio; Solucion de cloruro de sodio Sodium Chloride Solution; Solvente Cloruro de Sodio Sodium Chloride Solvent; Solvente de Cloruro de Sodio; Symbicort; Tacrolimus; Vitamin D; Xenon; Zithromax; Zitromax

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03283007 (ClinicalTrials.gov)	October 30, 2019	6/9/2017	Nintedanib in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome Grade 1-2	A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Transplant (LTx) Recipients With Bronchiolitis Obliterans Syndrome (BOS) Grade 1-2	Lung-transplant Recipients	Drug: Nintedanib;Drug: Placebo	Assistance Publique - Hôpitaux de Paris	NULL	Recruiting	18 Years	N/A	All	80	Phase 3	France
2	EUCTR2018-001747-31-FR (EUCTR)	09/04/2019	28/12/2018	A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Transplant (LTx) recipients with bronchiolitis obliterans syndrome (BOS) grade 1-2	A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Tranplant (LTx) recipients with bronchiolitis obliterans sydrome (BOS) grade 1-2 - INFINITX BOS	Bronchiolitis Obliterating Syndrome (SBO) grade 1 or 2 in patients with pulmonary transplantation. MedDRA version: 20.0;Level: PT;Classification code 10029888;Term: Obliterative bronchiolitis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]		ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	80	Phase 3	France
3	NCT03805477 (ClinicalTrials.gov)	March 20, 2019	8/1/2019	Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation	Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation (HSCT)- a Multicentre Phase II Trial	Bronchiolitis Obliterans Syndrome (BOS);Bronchiolitis Obliterans (BO)	Drug: Nintedanib	University Hospital, Basel, Switzerland	NULL	Recruiting	18 Years	N/A	All	40	Phase 2	Austria;Germany;Switzerland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03283007
(ClinicalTrials.gov)

October 30, 2019

6/9/2017

Nintedanib in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome Grade 1-2

A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Transplant (LTx) Recipients With Bronchiolitis Obliterans Syndrome (BOS) Grade 1-2

Lung-transplant Recipients

Drug: Nintedanib;Drug: Placebo

Assistance Publique - Hôpitaux de Paris

NULL

Recruiting

18 Years

N/A

All

Phase 3

France

EUCTR2018-001747-31-FR
(EUCTR)

09/04/2019

28/12/2018

A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Transplant (LTx) recipients with bronchiolitis obliterans syndrome (BOS) grade 1-2

A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Tranplant (LTx) recipients with bronchiolitis obliterans sydrome (BOS) grade 1-2 - INFINITX BOS

Bronchiolitis Obliterating Syndrome (SBO) grade 1 or 2 in patients with pulmonary transplantation.
MedDRA version: 20.0;Level: PT;Classification code 10029888;Term: Obliterative bronchiolitis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 3

France

NCT03805477
(ClinicalTrials.gov)

March 20, 2019

8/1/2019

Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation

Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation (HSCT)- a Multicentre Phase II Trial

Bronchiolitis Obliterans Syndrome (BOS);Bronchiolitis Obliterans (BO)

Drug: Nintedanib

University Hospital, Basel, Switzerland

NULL

Recruiting

18 Years

N/A

All

Phase 2

Austria;Germany;Switzerland